Viewing data from:

TRI-LINYAH

ANDA

ETHINYL ESTRADIOL; NORGESTIMATE | A090524 | NOVAST LABORATORIES LTD

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Tri-Linyah (2023)

Total Spending

$84K

Total Claims

3,442

Beneficiaries

622

Avg Cost/Unit

$0.58

Spending Trend

$105K(2019)→$113K(2020)→$102K(2021)→$92K(2022)→$84K(2023)

YoY Change:-1.0%

5yr CAGR:+4.4%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 0.035MG,0.035MG,0.035MG;0.18MG,0.215MG,0.25MG

0 patents0 exclusivities▴

TABLET;ORAL-28 | Approved: May 30, 2012

No patent or exclusivity listings for this strength.